The Protective Effects of Monophosphoryl Lipid A on the Ischemic Myocardium and Endothelium in Rats

Cardiovascular Drugs and Therapy

Volumn 17, Issue 4, 2003, Pages 311-318

  Zhu, Hui Qing ^a   Jiang, Jun Lin ^a   Lu, Rong ^a   Zhang, Xiao Hong ^a   Deng, Han Wu ^a   Li, Yuan Jian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Endothelium dysfunction; Inducible nitric oxide synthase; Low density lipoprotein (LDL); Monophosphoryl lipid A

Indexed keywords

ACETYLCHOLINE; AMINOGUANIDINE; ENDOTHELIUM DERIVED RELAXING FACTOR; LOW DENSITY LIPOPROTEIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHORYL LIPID A;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENDOTHELIUM CELL; ENDOTHELIUM LESION; HEART DISEASE; HEART FUNCTION; HEART INFARCTION PREVENTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ARGININE; CHOLESTEROL, LDL; CREATINE KINASE; ENDOTHELIUM, VASCULAR; HEART; LIPID A; MALE; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 0344197475     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027335321530     Document Type: Article

References (32)

1. Chang MY, Lees AM, Lees RS. Low-density lipoprotein modification and arterial wall accumulation in a rabbit model of atherosclerosis. Biochemistry 1993;32:8518-8524.
2. Hein TW, Kuo L. LDLs impair vasomotor function of the coronary microcirculation: Role of superoxide anions. Circ Res 1998;83:404-414.
3. Okuno S, Thoren P, Lowbeer C, Valen G. The role of nitric oxide in ischaemia/reperfusion injury of isolated hearts from severely atherosclerotic mice. Life Sci 2001;69:2067-2080.
4. Yu XJ, Li YJ, Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci 1994;54:753-758.
5. Boger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine: A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
6. Jiang JL, Li Ns NS, Li YJ, Deng HW. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002;135:1175-1182.
7. Yao Z, Elliott GT, Gross GJ. Monophosphoryl lipid A preserves myocardial contractile function following multiple, brief periods of coronary occlusion in dogs. Pharmacology 1995;51:152-159.
8. Baxter GF, Goodwin RW, Wright MJ, Kerac M, Heads RJ, Yellon DM. Myocardial protection after monophosphoryl lipid A: Studies of delayed anti-ischaemic properties in rabbit heart. Br J Pharmacol 1996;117:1685-1692.
9. Yoshida K, Maaieh MM, Shipley JB, et al. Monophosphoryl lipid A induces pharmacologic 'preconditioning' in rabbit hearts without concomitant expression of 70-kDa heat shock protein. Mol Cell Biochem 1996;156:1-8.
10. Zhao L, Weber PA, Smith JR, Comerford ML, Elliott GT. Role of inducible nitric oxide synthase in pharmacological " preconditioning" with monophosphoryl lipid A. J Mol Cell Cardiol 1997;29:1567-1576.
11. Elliott GT. Monophosphoryl lipid A induces delayed preconditioning against cardiac ischemia-reperfusion injury. J Mol Cell Cardiol 1998;30:3-17.
12. Peng J, Lu R, Ye F, Deng HW, Li YJ. The heme oxygenase-1 pathway is involved in calcitonin gene-related peptide-mediated delayed cardioprotection induced by monophosphoryl lipid A in rats. Regul Pept 2002;103:1-7.
13. Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation 1994;89:1254-1261.
14. Kaeffer N, Richard V, Francois A, Lallemand F, Henry JP, Thuillez C. Preconditioning prevents chronic reperfusion-induced coronary endothelial dysfunction in rats. Am J Physiol 1996;271(3 Pt 2):H842-H849.
15. Kaeffer N, Richard V, Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: Role of free radicals. Circulation 1997;96:2311-2316.
16. Richard V, Danielou E, Kaeffer N, Thuillez C. Delayed endothelial protective effects of monophosphoryl lipid A after myocardial ischemia and reperfusion in rats. J Mol Cell Cardiol 1999;31:1117-1123.
17. Salkowski CA, Detore G, Franks A, Falk MC, Vogel SN. Pulmonary and hepatic gene expression following cecal ligation and puncture: Monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration. Infect Immun 1998;66:3569-3578.
18. Gustafson GL, Rhodes MJ, Hegel T. Monophosphoryl lipid A as a prophylactic for sepsis and septic shock. Prog Clin Biol Res 1995;392:567-579.
19. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-3095.
20. Chen BM, Xia LW, Zhao RQ. Determination of N(G), N(G)-dimethylarginine in human plasma by high-performance liquid Chromatography. J Chromatogr B Biomed Sci Appl 1997;692:467-471.
21. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160-162.
22. Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990;87:904-908.
23. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991;90:119-126.
24. 2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation. Prostaglandins Leukot Essent Fatty Acids 2000;63:329-335.
25. Calara F, Dimayuga P, Niemann A, et al. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 1998;18:884-893.
26. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
27. Kurose I, Wolf R, Grisham MB, Granger DN. Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules. Am J Physiol 1995;268:H2224-H2231.
28. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patient with congestive heart failure. Life Sci 1998;62:2425-2430.
29. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-658.
30. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99-105.
31. Leiper JM, Santa, Maria J, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343(Pt 1):209-214.
32. Tran CT, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene structure, and expression pattern of DDAH1: Comparison with DDAH2 and implications for evolutionary origins. Genomics 2000;68:101-105.